Previous Close | 27.51 |
Open | 27.77 |
Bid | 25.00 x 2900 |
Ask | 26.15 x 800 |
Day's Range | 25.14 - 27.79 |
52 Week Range | 12.71 - 42.16 |
Volume | |
Avg. Volume | 1,470,450 |
Market Cap | 1.862B |
Beta (5Y Monthly) | 1.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.01 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 76.57 |
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint